Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745
- Citation:
- J Clin Oncol vol 29 (suppl) abstr 4116
- Meeting Instance:
- ASCO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2228
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- J. Hubbard S. Alberts W. Loui M. Mahoney L. Roberts T. Smyrk Z. Gatalica S. Kumar S. Dakhil P. Flynn M. Bury
- Networks:
- Study
- NCCTG-N0745
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: